Guidelines for the management of Community-Acquired Pneumonia in Saudi Arabia: A model for the Middle East region

International Journal of Antimicrobial Agents

Volumn 20, Issue SUPPL. 1, 2002, Pages 1-12

  Memish, Ziad A ^a   Shibl, Atef M ^b   Ahmed, Qanta A A ^c  

^a KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antibiotic resistance; Community acquired pneumonia; Saudi Arabia; Treatment guidelines

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; DOXYCYCLINE; MACROLIDE; PENICILLIN G; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE SEVERITY; DRUG COST; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; LEGIONELLA PNEUMOPHILA; MIDDLE EAST; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIA; NONHUMAN; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH SERVICE; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SAUDI ARABIA; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; TUBERCULOSIS; VACCINATION; ARTICLE; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; MICROBIOLOGY; PRACTICE GUIDELINE; STANDARD;

ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; RISK FACTORS; SAUDI ARABIA;

EID: 0036849580     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(02)00243-1     Document Type: Review

References (35)

1. Weingarten S. Translating practice guidelines into patient care: guidelines at the bedside. Chest. 118:2000;4S-7S.
2. The World Fact Book 2000, Central Intelligence Agency, Saudi Arabia.
3. Niederman M.S., McSombs J.S., Unger A.N., Kuma A., Popovan R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther. 20:1998;820-837.
4. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. J. Respir. Crit. Care Med. 163:2001;1730-1754.
5. The Drug Resistant Streptococcus pneumoniae Therapeutic Working Group, Heffelfinger J.D., Dowell S.F., Jorgensen J.H., et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from The Drug Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Int. Med. 160:(10):2000;1399-1408.
6. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Disease Society of America. Clin. Infect. Dis. 31:2000;347-382.
7. McFarlane J., Boswell T., Douglas G., et al. BTS Guidelines for the management of CAP in adults. Thorax. 56:(IV):2001.
8. Dean N.C., Silver M.P., Bateman K.A. Frequency of subspecialty physician care for elderly patients with community-acquired pneumonia. Chest. 117:2000;393-397.
9. Almirall J., Gonzalez C.A., Balanzo X., Bolibar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest. 116:1998;375-379.
10. Mandell L.A., Marrie T.J., Grossman R.F., Chow A.W., Hyland R.H. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin. Infect. Dis. 31:2000;383-421.
11. Marrie T.J., Durant H., Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev. Infect. Dis. 11:1989;586-599.
12. Kauppinen M.T., Herva E., Kujala P., Leinonen M., Saikku P., Syrjale H. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J. Infect. Dis. 172:1995;1330-1335.
13. Marston B.J., Plouffe J.F., File T.M. Jr., et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Ann. Int. Med. 157:1997;1709-1718.
14. Marrie T.J., Peeling R.W., Fine M.J., Singer D.E., Coley C.M., Kapoor W.N. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am. J. Med. 101:1996;508-515.
15. Langille D.B., Yates L., Marrie T.J. Serological investigation of pneumonia as it presents to the physicians office. Can. J. Infect. Dis. 4:1993;328-332.
16. Kuo C.C., Jackson L.A., Campbell L.A., Grayston J.T. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8:1995;451-461.
17. Mah M.W., Memish Z.A. Antibiotic resistance: an impending crisis. Saudi Med. J. 21:(12):2000;1125-1129.
18. Gleason P.P., Meehan T.P., Fine J.M., Galusha D.H., Fine M.J. Associations between initial antimicrobial regimens and medical outcomes for elderly patients with pneumonia. Arch. Int. Med. 159:1999;2562-2572.
19. Shibl A.M., Al Rasheed, Elbashier A.M., Osoba A.O. Penicillin resistant and intermediate Streptococcus pneumoniae in Saudi Arabia. J. Chemother. 12:2000;134-137.
20. The Alexander Project Group, Felmingham D., Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: findings of the Alexander Project 1992-1996. J. Chemother. 11:1999;5-21.
21. Shibl A.M., Memish Z.A., Osoba A. Antibiotic resistance in developing countries. J. Chemother. 13:(1):2001;40-44.
22. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard. 5th ed. (M7-A5):1999;National Committee for Clinical Laboratory Standards, Wayne, PA.
23. Pallares R., Linares J., Vadillo M., et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:1995;474-480.
24. Plouffe J.F., Breiman R.F., Facklam R.R. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. Franklin County Pneumonia Study Group l. J. Am. Med. Assoc. 275:1996;194-198.
25. Metlay J.P., Hoffman J., Cetron M.S., et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30:2000;520-528.
26. Feikin D.R., Schuchat A., Kolczak M., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health. 90:2000;223-229.
27. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low risk patients with CAP. N. Engl. J. Med. 336:1997;243-250.
28. Fine M.J., Medsger A.R., Stone R.A., et al. The hospital discharge decision for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch. Int. Med. 157:1997;47-56.
29. Marrie T.J., Lau C.Y., Wheeler S.L., Weng C.J., Vanderroort M.K., Feagan B.G. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. J. Am. Med. Assoc. 283:2000;749-755.
30. Atlas S.J., Benzer T.I., Borowsky L.H., et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch. Int. Med. 158:1998;1350-1356.
31. Marras T.K., Guterrez C., Chan C.K. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. Chest. 118:2000;1339-1343.
32. Marras T.K., Lee-Pack L., Jamieson L., Chan C.K. Guidelines adherence and clinical outcomes in community-acquired pneumonia: are new guidelines improving outcomes? Chest. 118:2000;111S.
33. Butler J.C., Cetron M.S. Pneumococcal resistance: The new 'special enemy of old age'. Clin. Infect. Dis. 28:1998;730-735.
34. Koivula I., Sten M., Leinonen M., Makela P.H. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single blind population-based trial. Am. J. Med. 103:1997;281-290.
35. Memish Z, Balkhy H, Shibl A, Barbozoc G, Gray GC. Streptococcus pneumonia in Saudi Arabia: antibiotic resistance and serotypes among recent clinical isolates, Int. J. Infect. Dis., submitted for publication.